4 research outputs found
Effect of glutamine analogue-acivicin on tumor induced angiogenesis in Ehrlich ascites carcinoma
407-413The inhibition of tumor growth and tumor
induced angiogenesis by the glutamine antimetabolite acivicin was evaluated in
6-7 weeks old male Swiss albino mice bearing Ehrlich ascites carcinoma (EAC) transplanted
by intraperitoneal (ip) injections of EAC cells. Treatment involving ip injections
with two different doses of acivicin (0.05 and 0.4μg/g body weight/day)
in saline revealed decrease in tumor volumes and reduced number of blood vessels
on peritoneal wall after 10 and 15 days of treatment when compared to control (i.e.
injected with saline only). Vascular hyperpermeability was found to be lesser in
the treated groups of mice than the control as indicated by the FITC-D and colloidal
carbon assay. Serum VEGF level was found to decrease in the drug treated groups
both after 10 and 15 days of treatment. The results thus suggest that acivicin may
suppress tumoral angiogenesis through regulation of VEGF level
Neovascularisation offers a new perspective to glutamine related therapy
88-90Angiogenesis or the generation of new
blood vessel, is an important factor in the growth of a solid tumor. Hence, it becomes
a necessary parameter of any kind of therapeutic study. Glutamine is an essential
nutrient of tumor tissue and glutamine related therapy involves clearance of
circulatory glutamine by glutaminase. Therefore, using different murine solid tumor
models, the present study was undertaken to find out whether the S-180 cell
glutaminase has any effect on angiogenesis of solid tumor, or not. Result
indicates that the purified S-180 cell glutaminase reduces tumor volume and restrict
the generation of neo blood vessels. Therefore, it can be concluded that this enzyme
may be an effective device
against the cancer metastasis
Acivicin with glutaminase regulates proliferation and invasion of human MCF-7 and OAW-42 cells-An <i style="">in vitro</i> study
22-26Tumor cells intensely utilize glutamine as the major source of respiratory fuel. Glutamine-analogue acivicin inhibits tumor growth and tumor-induced angiogenesis in Ehrlich ascites carcinoma. In the present study, antitumor properties of acivicin in combination with glutaminase enzyme is reported. Acivicin along with E. coli glutaminase synergistically reduced in vitro proliferation and matrigel invasion of human MCF-7 and OAW-42 cells. Effects of single and combined treatments with acivicin and glutaminase on angiogenic factors were also analyzed in these cell lines. Co-administration of the treatment agents inhibits the release of VEGF and MMP-9 by cells in culture supernatant significantly than single agent treatments. The result suggests that combination of acivicin with glutaminase may provide a better therapeutic option than either of them given separately for treating human breast and ovarian cancer. However, further studies are required to be conducted in vivo for its confirmation